Central Hospital Of Northern Pest Military Hospital
- Address
- lock Available on a paid plan
Central Hospital Of Northern Pest Military Hospital - Advanced Clinical Research Center
The Central Hospital Of Northern Pest Military Hospital operates as a comprehensive clinical research facility, conducting cutting-edge trials across multiple therapeutic domains. The center demonstrates particular expertise in cardiovascular diseases, oncology, and metabolic disorders, participating in pivotal international Phase 2 and Phase 3 studies that advance therapeutic options for complex medical conditions.
- Cardiovascular Research: Heart failure (HFrEF and HFpEF), atrial fibrillation, hypertrophic cardiomyopathy, and innovative gene therapy approaches for congestive heart failure
- Oncology Studies: Advanced solid tumors, breast cancer (HER2-positive, triple-negative, hormone receptor-positive), gastric adenocarcinoma, urothelial carcinoma, head and neck cancer, and prostate cancer with targeted therapies and immunotherapy combinations
- Metabolic and Endocrine Disorders: Type 2 diabetes, acromegaly, severe hypertriglyceridemia, and obesity with focus on cardiovascular safety outcomes
- Ophthalmology: Diabetic macular edema, age-related macular degeneration (wet and dry AMD with geographic atrophy), and acquired blepharoptosis
The facility also conducts specialized research in autoimmune and inflammatory conditions including Crohn's disease, ulcerative colitis, and psoriatic arthritis, as well as rare disease studies encompassing hemophilia A and B, short bowel syndrome, and primary biliary cholangitis. The center's participation in first-in-human studies and long-term extension trials demonstrates its capability to manage complex protocols across the full spectrum of drug development, from early-phase investigations to real-world evidence generation in acute kidney injury and other critical conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 149 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 147 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
- 1AstraZeneca AB2active
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB13trials
lock +18 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Central Hospital Of Northern Pest Military Hospital
lock Showing 1 of 99 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA) | AstraZeneca AB | Phase I/II | Not Recruiting | Jul 2021 | — |
IMP list
lock Showing 1 of 149 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 6 | Unknown | 2020-04-09 | 2022-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.